Study title:
Gene therapy for the treatment of glioblastoma multiforme with in vivo tumor transduction with the herpes simplex thymidine kinase gene /ganciclovir system
Date receipt dossier:
2 jan 1996
Pharmaceutical study code:
GLIB 201-E-00
Company / Sponsor:
Sandoz Pharma, LTD
Phase:
II
Indication category:
Cancer therapy
Disease:
Newly diagnosed or recurrent Glioblastoma multiforme
Therapeutic approach:
Suicide gene/ pro drug
Genetic modification:
Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR)
Method of transfer of nucleic acid of interest:
Amphotropic Murine Leukemia Virus
Administered biological material:
Retroviral vector producing cells (PA 317)
Route of administration:
Intratumoral
Locations in Belgium:
Hôpital Erasme, Brussels
Type of procedure:
Contained use only
Current status:
Authorized